Nightingale Health launches new website aligned with the B2B and B2G strategy
Nightingale Health Plc, Press release
21 May 2024 at 11:15 a.m. (EEST)
Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, announces the launch of its updated website: https://nightingalehealth.com/
The new website highlights Nightingale Health’s main product: the most advanced Health Check for the health industry, and the website is designed to demonstrate the value Nightingale’s Health Check provides to customers.
The website change follows the company’s strategy update in the autumn with focus on B2B and B2G markets. Since the strategy update, Nightingale Health has already successfully executed the strategy with Finland’s largest private healthcare provider, Terveystalo, that has replaced clinical chemistry tools with Nightingale Health’s risk prediction models in routinely performed health checks which cover approximately 30% of the Finnish working population. In addition, the company has announced agreements in Asia and the United States that are further indications of the successful implementation of the B2B and B2G strategy. The new website introduces different use cases of the technology built on the company’s strengths and the already announced achievements.
On the renewed website, customers and other visitors can easily find more information about the company’s products: the Health Check powered by Nightingale Health, the Remote Health Check powered by Nightingale Health and the services for research; CoreMetabolomics™ and RemoteOmics™.
For further information, please contact:
Teemu Suna, CEO
[email protected]
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/
